General
Preferred name
CARTEOLOL
Synonyms
Arteoptic ()
Abbott-43326 ()
OPC-1085 hydrochloride ()
Carteolol HCl ()
Mikelan ()
CARTEOLOL HYDROCHLORIDE ()
Carteolol hydrochloride,OPC-1085 hydrochloride ()
Carteolol (hydrochloride) ()
OPC-1085 ()
Ocupress ()
Cartrol ()
NSC-300906 ()
Teoptic ()
P&D ID
PD009980
CAS
51781-21-6
51781-06-7
Tags
available
drug
Approved by
FDA
First approval
1988
Drug indication
Glaucoma/ocular hypertension
Cardiovascular disease
Open-angle glaucoma
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.
PRICE 29
DESCRIPTION Carteolol is a β-blocker, selective for β1-adrenoceptors in cardiac tissue. (GtoPdb)
DESCRIPTION Carteolol hydrochloride (Abbott-43326) is a synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for the treatment of hypertension and certain arrhythmias and as an anti-angina and antiglaucoma agent. (TargetMol Bioactive Compound Library)
Compound Sets
21
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
292.18
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
1
cLogP
1.7
TPSA
70.59
Fraction CSP3
0.56
Chiral centers
1.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
β-adrenergic receptor
ADRB1, ADRB2, ADRB3
Indication
intraocular pressure, glaucoma, ocular hypertension
MOA
Adrenergic Receptor antagonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Therapeutic Class
Antihypertensive Agents
Source data